{
  "description": "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2021 zu 2022. In diesem Jahr erfolgte die größte Reklassifikation der onkologischen ATC-Systematik: die monoklonalen Antikörper wurden aus der Sammelgruppe L01XC in die neue, nach Zielstruktur gegliederte Gruppe L01F überführt.",
  "sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
  "_filename": "ConceptMap-mii-cm-onko-atc-transitions-2022.json",
  "package_name": "de.medizininformatikinitiative.kerndatensatz.onkologie",
  "date": "2026-08-25",
  "group": [ {
    "source": "http://fhir.de/CodeSystem/bfarm/atc",
    "target": "http://fhir.de/CodeSystem/bfarm/atc",
    "element": [ {
      "code": "L01XC02",
      "target": [ {
        "code": "L01FA01",
        "comment": "Reklassifizierung zu CD20-Inhibitoren",
        "display": "Rituximab",
        "equivalence": "equivalent"
      } ],
      "display": "Rituximab"
    }, {
      "code": "L01XC15",
      "target": [ {
        "code": "L01FA03",
        "comment": "Reklassifizierung zu CD20-Inhibitoren",
        "display": "Obinutuzumab",
        "equivalence": "equivalent"
      } ],
      "display": "Obinutuzumab"
    }, {
      "code": "L01XC26",
      "target": [ {
        "code": "L01FB01",
        "comment": "Reklassifizierung zu CD22-Inhibitoren",
        "display": "Inotuzumab ozogamicin",
        "equivalence": "equivalent"
      } ],
      "display": "Inotuzumab ozogamicin"
    }, {
      "code": "L01XC24",
      "target": [ {
        "code": "L01FC01",
        "comment": "Reklassifizierung zu CD38-Inhibitoren",
        "display": "Daratumumab",
        "equivalence": "equivalent"
      } ],
      "display": "Daratumumab"
    }, {
      "code": "L01XC03",
      "target": [ {
        "code": "L01FD01",
        "comment": "Reklassifizierung zu HER2-Inhibitoren",
        "display": "Trastuzumab",
        "equivalence": "equivalent"
      } ],
      "display": "Trastuzumab"
    }, {
      "code": "L01XC13",
      "target": [ {
        "code": "L01FD02",
        "comment": "Reklassifizierung zu HER2-Inhibitoren",
        "display": "Pertuzumab",
        "equivalence": "equivalent"
      } ],
      "display": "Pertuzumab"
    }, {
      "code": "L01XC14",
      "target": [ {
        "code": "L01FD03",
        "comment": "Reklassifizierung zu HER2-Inhibitoren",
        "display": "Trastuzumab emtansin",
        "equivalence": "equivalent"
      } ],
      "display": "Trastuzumab emtansin"
    }, {
      "code": "L01XC06",
      "target": [ {
        "code": "L01FE01",
        "comment": "Reklassifizierung zu EGFR-Inhibitoren",
        "display": "Cetuximab",
        "equivalence": "equivalent"
      } ],
      "display": "Cetuximab"
    }, {
      "code": "L01XC08",
      "target": [ {
        "code": "L01FE02",
        "comment": "Reklassifizierung zu EGFR-Inhibitoren",
        "display": "Panitumumab",
        "equivalence": "equivalent"
      } ],
      "display": "Panitumumab"
    }, {
      "code": "L01XC17",
      "target": [ {
        "code": "L01FF01",
        "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren",
        "display": "Nivolumab",
        "equivalence": "equivalent"
      } ],
      "display": "Nivolumab"
    }, {
      "code": "L01XC18",
      "target": [ {
        "code": "L01FF02",
        "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren",
        "display": "Pembrolizumab",
        "equivalence": "equivalent"
      } ],
      "display": "Pembrolizumab"
    }, {
      "code": "L01XC28",
      "target": [ {
        "code": "L01FF03",
        "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren",
        "display": "Durvalumab",
        "equivalence": "equivalent"
      } ],
      "display": "Durvalumab"
    }, {
      "code": "L01XC31",
      "target": [ {
        "code": "L01FF04",
        "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren",
        "display": "Avelumab",
        "equivalence": "equivalent"
      } ],
      "display": "Avelumab"
    }, {
      "code": "L01XC32",
      "target": [ {
        "code": "L01FF05",
        "comment": "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren",
        "display": "Atezolizumab",
        "equivalence": "equivalent"
      } ],
      "display": "Atezolizumab"
    }, {
      "code": "L01XC07",
      "target": [ {
        "code": "L01FG01",
        "comment": "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren",
        "display": "Bevacizumab",
        "equivalence": "equivalent"
      } ],
      "display": "Bevacizumab"
    }, {
      "code": "L01XC21",
      "target": [ {
        "code": "L01FG02",
        "comment": "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren",
        "display": "Ramucirumab",
        "equivalence": "equivalent"
      } ],
      "display": "Ramucirumab"
    }, {
      "code": "L01XC11",
      "target": [ {
        "code": "L01FX04",
        "comment": "Reklassifizierung zu andere monoklonale Antikörper",
        "display": "Ipilimumab",
        "equivalence": "equivalent"
      } ],
      "display": "Ipilimumab"
    }, {
      "code": "L01XC12",
      "target": [ {
        "code": "L01FX05",
        "comment": "Reklassifizierung zu andere monoklonale Antikörper",
        "display": "Brentuximab vedotin",
        "equivalence": "equivalent"
      } ],
      "display": "Brentuximab vedotin"
    }, {
      "code": "L01XC19",
      "target": [ {
        "code": "L01FX07",
        "comment": "Reklassifizierung zu andere monoklonale Antikörper",
        "display": "Blinatumomab",
        "equivalence": "equivalent"
      } ],
      "display": "Blinatumomab"
    }, {
      "code": "L01XC27",
      "target": [ {
        "code": "L01FX10",
        "comment": "Reklassifizierung zu andere monoklonale Antikörper",
        "display": "Olaratumab",
        "equivalence": "equivalent"
      } ],
      "display": "Olaratumab"
    } ]
  } ],
  "meta": {
    "profile": [ "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap", "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap" ],
    "extension": [ {
      "url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
      "valueCode": "CC-BY-4.0"
    }, {
      "url": "http://hl7.org/fhir/StructureDefinition/package-source",
      "extension": [ {
        "url": "packageId",
        "valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
      }, {
        "url": "version",
        "valueString": "2027.0.0-ballot.1"
      }, {
        "url": "uri",
        "valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
      } ]
    } ]
  },
  "publisher": "Medizininformatik Initiative",
  "jurisdiction": [ {
    "coding": [ {
      "code": "DE",
      "system": "urn:iso:std:iso:3166",
      "display": "Germany"
    } ]
  } ],
  "purpose": "Migration von ATC-Codes für monoklonale Antikörper, die 2022 von L01XC nach L01F umkodiert wurden.",
  "name": "MII_CM_Onko_ATC_Transitions_2022",
  "type": null,
  "experimental": "false",
  "resourceType": "ConceptMap",
  "title": "MII CM Onko ATC Code Changes 2021 to 2022",
  "package_version": "2027.0.0-ballot.1",
  "extension": [ {
    "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode": "shareable"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode": "publishable"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
    "valueCodeableConcept": {
      "coding": [ {
        "code": "package",
        "system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
        "display": "Package"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
    "valueDate": "2026-09-15"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
    "valueCodeableConcept": {
      "coding": [ {
        "code": "C3262",
        "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
    "valueContactDetail": {
      "telecom": [ {
        "value": "thomas.debertshaeuser@charite.de",
        "system": "email"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
    "valueContactDetail": {
      "name": "Taskforce Core Data Set"
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
    "valueContactDetail": {
      "name": "Interoperability Working Group",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
    "valueContactDetail": {
      "name": "National Steering Committee",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
    "valueContactDetail": {
      "name": "Interoperability Working Group",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
    "valueContactDetail": {
      "name": "National Steering Committee",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
    "valueCoding": {
      "code": "semver",
      "system": "http://hl7.org/fhir/version-algorithm",
      "display": "SemVer"
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
    "valuePeriod": {
      "start": "2027"
    }
  } ],
  "targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2022",
  "status": "active",
  "id": "8f70f966-51d1-410a-8802-eb7a019de39c",
  "kind": null,
  "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2022",
  "version": "2027.0.0-ballot.1",
  "contact": [ {
    "name": "Medizininformatik Initiative",
    "telecom": [ {
      "value": "https://www.medizininformatik-initiative.de/",
      "system": "url"
    } ]
  } ]
}